GDP
ANIK icon

Great Diamond Partners’s Anika Therapeutics ANIK Stock Holding History

Great Diamond Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-853
Closed -$44K – 145
2019
Q4 		$44K Buy
+853
New +$49.5K 0.02% 312

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Great Diamond Partners's ANIK Position: Q1 2020 in Review

Great Diamond Partners sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 853 shares — an estimated $44K sold.

Great Diamond Partners first reported a position in ANIK in Q4 2019 and held it in 1 quarter. The position peaked at $44K in Q4 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Great Diamond Partners reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Great Diamond Partners sold 853 Anika Therapeutics shares in Q1 2020, an estimated $44K.
  • Great Diamond Partners first reported a position in Anika Therapeutics in Q4 2019 and held it in 1 quarter.
  • Great Diamond Partners's Anika Therapeutics position peaked at $44K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Great Diamond Partners's 13F filing for Q1 2020, filed 1 May 2020.